CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV - News) today reported that it has completed its open-label multi-dose, multi-day, observational safety study of Dyloject in the United States and that the study successfully met its objective.
